|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mutations in genes important in drug absorption, distribution, metabolism and excretion (ADME) play a critical role in pharmacogenetics of diabetes.There are currently five major classes of oral pharmacological agents available to treat type 2 diabetes: sulfonylureas, meglitinides, metformin (a biguanide), thiazolidinediones, and α-glucosidase inhibitors.
|
21169132 |
2010 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The animal experiments showed that diabetes increased intestinal disaccharidase activities, accompanied by high mRNA and protein expression of SI complex.
|
21946084 |
2011 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B) and α-glucosidase are important targets to treat obesity and diabetes, due to their deep correlation with insulin and leptin signalling, and glucose regulation.
|
28933230 |
2017 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
On the basis of previous report on promising α-glucosidase inhibitory activity of 5-bromo-2-aryl benzimidazole derivatives, these derivatives were further screened for urease inhibitory and cytotoxicity activity in order to get more potent and non-cytotoxic potential dual inhibitor for the patients suffering from diabetes as well as peptic ulcer.
|
28346872 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lxn significantly inhibited (p < 0.05) the activity of α-amylase and α-glucosidase and could be of medical and nutritional relevance in the treatment of diabetes.
|
28170007 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
As the close correlation between α-glucosidase inhibitors and the treatment of diabetes, in combination with capillary electrophoresis (CE), a method was developed to screen α-glucosidase inhibitors from traditional Chinese medicines (TCMs) by immobilizing α-glucosidase on magnetic nanoparticles.
|
28107971 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
α-Glucosidase and α-amylase inhibitors from seed oil: A review of liposoluble substance to treat diabetes.
|
26854322 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibitory potential against key enzymes involved in diabetes (α-glucosidase and α-amylase), obesity (pancreatic lipase), neurodegenerative diseases (cholinesterases), and hyperpigmentation (tyrosinase) was evaluated.
|
28040595 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
α-Glucosidase enzymes contribute to the digestion of starch into glucose and are thus attractive therapeutic targets for diabetes.
|
29548257 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Enzyme inhibitory potential was assessed against key enzymes linked to global health problems, namely neurodegenerative diseases (acetylcholinesterase), pigmentation (tyrosinase), and diabetes (α-amylase and α-glucosidase).
|
29169111 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
α-Glucosidase plays an important role in carbohydrate metabolism and is therefore an attractive therapeutic target for the treatment of diabetes, obesity and other related complications.
|
30282319 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gray, and <i>Salvia officinalis</i> L. decoctions were investigated for their health-benefit properties, in particular with respect to antioxidant activity and inhibitory ability towards key enzymes with impact in diabetes and obesity (α-glucosidase, α-amylase and pancreatic lipase).
|
30513773 |
2018 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The inhibition of α-glucosidase, a key carbohydrate hydrolyzing enzyme, could serve as one of the effective methodology in both preventing and treating diabetes through controlling the postprandial glucose levels and suppressing postprandial hyperglycemia.
|
29421697 |
2018 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Accordingly, nutritional composition, the content of phytochemical antioxidants, and the inhibitory ability of key enzymes with impacts on obesity and diabetes (α-glucosidase and pancreatic lipase) or on arterial pressure (angiotensin-I converting enzyme), were evaluated.
|
30274353 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Scopoletin inhibits α-glucosidase in vitro and alleviates postprandial hyperglycemia in mice with diabetes.
|
30031794 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study sets out to investigate into antioxidant and inhibitory activities of O. argyrea extracts (ethyl acetate, methanol, and water) against key enzymes linked to diabetes (α-amylase, α-glucosidase), Alzheimer's disease (acetylcholinesterase, butyrylcholinesterase), and skin hyperpigmentation (tyrosinase).
|
30081342 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken altogether, in vitro and in vivo experiments suggest that selected natural compounds (curcumin, antroquinonol, HCD, docosanol, tetracosanol, rutin, and actinodaphnine) via molecular docking were confirmed as potential candidates of α-glucosidase and α-amylase inhibitors for treating diabetes.
|
30189596 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results demonstrate that ultrafiltration with liquid chromatography and mass spectrometry combined with high-speed counter-current chromatography is not only a powerful tool for screening and isolating α-glucosidase and lactate dehydrogenase inhibitors in complex samples, but also a useful platform for identifying bioactive compounds for preventing and treating diabetes and stroke.
|
30444083 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cratoxylum cochinchinense displayed significant inhibition against protein tyrosine phosphatase 1B (PTP1B) and α-glucosidase, both of which are key target enzymes to attenuate diabetes and obesity.
|
29306546 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The inhibitory action of F. halophila extracts (acetone, chloroform, and methanol) against key enzymes linked to diabetes (α-amylase, α-glucosidase), cognitive functions (acetyl cholinesterase (AChE), butyryl cholinesterase (BChE)), and hyperpigmentation (tyrosinase) was assessed.
|
30121555 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The findings of this work supported that N. oleracea is a rich source of phenolics that can be potential antioxidants and α-glucosidase inhibitors for the management of diabetes.
|
30616569 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
α-Glucosidase and its inhibitors play a key role in diagnosis and treatment of diabetes.
|
31670357 |
2019 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Increased α-glucosidase, PEPCK, GLUT-2 and SGLTs levels with the induction of diabetes considerably lowered with TPSE treatment.
|
30399410 |
2019 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Chalcones, originated from natural product, have been broadly studied their biological activity against various proteins which at the molecular level, are responsible for the progress of the diseases in cancer (e.g. kinases), inflammation (oxidoreductases), atherosclerosis (cathepsins receptor), and diabetes (e.g.α-glucosidase).
|
31808389 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
α-Glucosidase inhibitors have been approved as therapeutic agents for diabetes.
|
31555798 |
2019 |